




RealRate

PHARMACEUTICAL 2023

Rhythm Pharmaceuticals INC
Rank 220 of 471

Rhythm
PHARMACEUTICALS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Rhythm Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rhythm Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Rhythm Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 273%, being 29% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	354,236
Cost of Goods Sold	2,133
Intangible Assets	7,883
Liabilities, Current	39,809
Liabilities, Non-Current	1,260
Other Assets	18,165
Other Compr. Net Income	-91
Other Expenses	0
Other Liabilities	77,150
Other Net Income	-1,962
Other Revenues	23,638
Property and Equipment	2,197
Research and Development	108,630
Selling, General and Administrative Expense	92,032

Output Variable	Value in 1000 USD
Assets	382,481
Liabilities	118,219
Expenses	202,795
Revenues	23,638
Stockholders Equity	264,262
Net Income	-181,119
Comprehensive Net Income	-181,164
BaseVar	364,593
ECR before Limited Liability	158%
Economic Capital Ratio	273%